---
title: "Bio-S released its performance for the first half of the year, with a net profit attributable to the parent company of 3.0982 million yuan, a decrease of 97.69%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254660462.md"
description: "According to the Zhitong Finance APP, Bio-S released its semi-annual report for 2025, showing that the company's operating revenue was 332 million yuan, a year-on-year decrease of 36.70%. The net profit attributable to shareholders of the listed company was 3.0982 million yuan, a year-on-year decrease of 97.69%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 11.7301 million yuan. The basic earnings per share were 0.03 yuan"
datetime: "2025-08-26T14:47:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254660462.md)
  - [en](https://longbridge.com/en/news/254660462.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254660462.md)
generator: "portal-rs"
---

# Bio-S released its performance for the first half of the year, with a net profit attributable to the parent company of 3.0982 million yuan, a decrease of 97.69%

According to the Zhitong Finance APP, Bio-S (301096.SZ) released its semi-annual report for 2025, reporting an operating income of 332 million yuan, a year-on-year decrease of 36.70%. The net profit attributable to shareholders of the listed company was 3.0982 million yuan, a year-on-year decrease of 97.69%. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 11.7301 million yuan. The basic earnings per share were 0.03 yuan

### Related Stocks

- [301096.CN](https://longbridge.com/en/quote/301096.CN.md)

## Related News & Research

- [Zealand Pharma (CPSE:ZEAL) Reports Weaker Earnings, Is It Still Below Fair Value?](https://longbridge.com/en/news/297245804.md)
- [FGMA Rises to No. 38 in BD+C's 2026 Top 200 Architecture Firms Ranking](https://longbridge.com/en/news/297187912.md)
- [BIDU-SW  to Pursue Dual Primary Listing on HKEX and Nasdaq Starting Next Tue](https://longbridge.com/en/news/297102765.md)
- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)
- [ByHeart Says FDA Confirms Review Of ByHeart's Root Cause Investigation And Action Plan](https://longbridge.com/en/news/297358769.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**